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Abstract GDP-D-mannose-4,6-dehydratase (GMD) is the key
enzyme in the ‘de novo’ pathway of GDP-L-fucose biosynthesis.
The reported cDNA sequences for human GMD predict three
forms of different length, whose ‘in vivo’ occurrence and
molecular properties are completely undefined. Here, we report
the expression in Escherichia coli and the properties of each
native recombinant GMD form. Only the 42 kDa long GMD (L-
GMD) and the 40.2 kDa (M-GMD) forms were recovered as
soluble functional proteins, while the 38.7 kDa form, short GMD
(S-GMD), lacking an N-terminal domain critical for dinucleotide
binding, was inactive and formed a precipitate. Both L-GMD
and M-GMD are homodimers and contain 1 mol of tightly bound
NADP+. Their kinetic properties (Km, Kcat) are apparently
identical and both forms are non-competitively feedback-
inhibited by GDP-L-fucose to a similar extent. M-GMD is the
predominant enzyme form expressed in several human cell lines.
These data seem to suggest that modulation of the ‘de novo’
pathway of GDP-L-fucose biosynthesis involves mechanisms
other than differential ‘in vivo’ expression of GMD forms.
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1. Introduction
GDP-D-mannose-4,6-dehydratase (GMD) (EC 4.2.1.47) is
the ¢rst enzyme involved in the ‘de novo’ pathway of GDP-
L-fucose biosynthesis, converting GDP-D-mannose to GDP-
4-keto-6-deoxy-D-mannose. This pathway, initially described
by Ginsburg in Aerobacter aerogenes [1,2], was then also iden-
ti¢ed in animals and plants [3^8]. GDP-L-fucose is the sub-
strate for fucosyltransferases which catalyze the insertion of
the deoxyhexose in a number of glycoconjugates in the Golgi
apparatus [9]. L-fucose-containing oligosaccharides, in partic-
ular antigens of the Lewis system, such as Lex and SLex have
been demonstrated to be the physiological ligands for selectins
and to play a critical role in the processes of rolling and
extravasation of leukocytes beyond the endothelial barrier
that start the in£ammation [10^12].
Recently, the cDNA for GMD has been cloned from hu-
man HL-60 cells [13]. The cDNA sequence predicts a protein
with two possible initiation methionines, corresponding to 42
kDa, long GMD (L-GMD) and to 40.2 kDa, medium GMD
(M-GMD), respectively, and showing a 60% identity with the
Escherichia coli enzyme. The human protein, starting at the
second methionine (M-GMD), was expressed in E. coli as a
fusion protein containing a His-leader sequence and was par-
tially characterized [13]. An identical cDNA sequence was
observed for GMD independently cloned from human lym-
phocytes in our laboratory [14]. A second cDNA sequence,
encoding a shorter human GMD protein of approximately
38.7 kDa, short GMD (S-GMD), and lacking the N-terminal
fragment, was proposed by another research group [15]. They
isolated a cDNA from a human fetal brain library that was
able to restore L-fucose production in the Lec-13 CHO clone,
in which GMD activity is defective.
Since GMD represents the limiting step in the metabolic
pathway for the ‘de novo’ production of GDP-L-fucose, we
undertook a study aimed at to better characterize the struc-
tural and kinetic properties of this enzyme in human cells. As
at least three slightly di¡erent proteins can derive from the
cDNA sequences reported so far, all of them were expressed
as glutathione transferase (GST) fusion proteins in E. coli and
the properties of each native protein obtained after proteolytic
removal of the GST tag were then investigated. Furthermore,
the patterns of expression of the three GMD forms were an-
alyzed in a panel of human cell lines.
2. Materials and methods
2.1. Protein expression and puri¢cation
The three putative forms of GMD, whose N-terminal sequences are
reported in Fig. 1B, were expressed in E. coli as fusion proteins with
GST, using pGEX-6P1 vector (Pharmacia, Milan, Italy). Total RNA
was obtained from human blood lymphocytes using Trizol reagent
(Life Technologies Italia, Milan, Italy) and was retrotranscribed using
oligo-dT and MuMV-RT (Promega, Madison, WI, USA) as described
[16]. The resulting cDNA was ampli¢ed using gene speci¢c primers1,
which were obtained by TibMolBiol (Genova, Italy). PCR conditions
were as previously described [14]. After puri¢cation, the products of
ampli¢cation were ligated in the pGEX-6-P1 vector. A competent E.
coli K803 strain was used for transformation.
Conditions for the expression of L- and M-GMD were as reported
previously [14,17]. Due to the formation of inclusion bodies, which
could not be prevented using di¡erent induction conditions, bacterial
cells expressing the shortest GMD form (S-GMD) were lysed using
sarkosyl, following the published protocol [18]. The fusion proteins
were puri¢ed by a⁄nity chromatography using GSH-Sepharose
(Pharmacia), following the supplier’s instructions. Cleavage of the
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L-GMD and M-GMD and under GenBank accession number
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FEBS 22430 6-8-99
FEBS 22430FEBS Letters 456 (1999) 370^374
native forms of GMD from the matrix-bound fusion proteins was
achieved using Prescission Protease (Pharmacia) upon incubation
for 16 h at 4‡C in 50 mM Tris-HCl bu¡er, pH 7.5, containing
1 mM Na2EDTA and 1 mM dithiothreitol (DTT).
2.2. Structural characterization and determination of apoenzyme-bound
NAD+/NADP+
The molecular weight and the purity of the recombinant proteins
were analyzed by 12% discontinuous sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) [19] and by Western blot-
ting. After blotting, the membrane was incubated with a rabbit poly-
clonal antibody raised against bacterial GMD [14], which, due to the
sequence identity of the proteins between the two species (more than
60%), is cross-reactive with human GMD. Detection was performed,
using a peroxidase-labelled secondary antibody, with the ECL system
(Amersham, Milan, Italy). Protein was estimated by the Bradford
method [20], using bovine serum albumin (BSA) as standard. The
oligomeric structure of the protein was investigated by gel ¢ltration
and by crosslinking experiments, using bis(sulfosuccinimidyl)suberate
(BS3) (Pierce, Rockford, IL, USA). Gel ¢ltration was performed as
described [21]. For BS3 experiments, the proteins were extensively
dialyzed against phosphate-bu¡ered saline (PBS) containing 1 mM
DTT. GMD (100 Wg/ml) was then incubated in PBS with increasing
concentrations of BS3, to de¢ne the optimal reaction conditions, for
1 h a 4‡C, either in the presence or absence of 1 mg/ml BSA. The
reaction was then stopped by incubating for 30 min at room temper-
ature in the presence of Tris-HCl, pH 8.0, at a 50 mM ¢nal concen-
tration and the samples were analyzed by Western blotting.
The presence of tightly protein-bound dinucleotide cofactors was
investigated by a highly sensitive enzymatic cycling assay [17]. To
avoid interference due to presence of DTT in the cleavage bu¡er,
the puri¢ed proteins were extensively dialyzed against 100 mM so-
dium phosphate bu¡er, pH 8.0, prior to the assay.
2.3. Determination of kinetic properties
The enzymatic activity of the puri¢ed proteins was determined by
high performance liquid chromatography and thin layer chromatog-
raphy analyses as described [21], using as substrate GDP-D-
[U-14C]mannose (Amersham) at a ¢nal speci¢c activity of 23U1010
Bq/mol. Unlabelled GDP-D-mannose, NAD, NADP, NADPH and
the compounds tested for inhibition studies (GDP-L-L-fucose, GDP-
K-L-fucose, GDP-D-glucose, GMP, GDP, GTP, L-l-fucose-1-P and
L-fucose) were from Sigma Chemicals (St. Louis, MO, USA). Incuba-
tions were performed in 100 mM sodium phosphate bu¡er, pH 8.0,
containing 2 mg/ml BSA. Km and Vmax values of the enzymes were
calculated by double-reciprocal plot treatment of kinetic data using
linear regression, on at least three di¡erent preparations of the pro-
teins. All kinetic experiments were carried out immediately after pu-
ri¢cation of the GMD forms.
2.4. Cell culture conditions
Cell lines HepG2, Hct-8, MCF7, SKNSH (obtained from ATCC:
Rockville, MD, USA) were grown in DMEM, supplemented with
10% FCS and 4 mM glutamine. The Jurkat cell line (ATCC) was
maintained in RPMI 1640 supplemented with 10% FCS and 2 mM
glutamine. To minimize proteolysis, Western blot analysis was per-
formed following addition of boiling 2USDS-PAGE loading bu¡er
(2Ubu¡er: 125 mM Tris-HCl, pH 6.5, 200 mM DTT, 4% SDS, 20%
glycerol and 0.02% bromophenol blue) directly to culture £asks, pre-
viously washed twice with ice-cold PBS. Western blot conditions were
as reported above (Section 2.2).
3. Results
3.1. Expression of multiple recombinant forms of human GMD
Following expression and lysis by standard procedures, pu-
ri¢cation by a⁄nity chromatography and cleavage by Prescis-
sion protease, both L-GMD and M-GMD forms were ob-
tained as homogeneous proteins of the expected molecular
weight, as shown by SDS-PAGE and Western blot analysis
(Fig. 1A and B). Recovery ranged from 0.6 to 1 mg of pure
protein per l of bacterial culture. Conversely, since S-GMD
was recovered only in inclusion bodies despite several di¡erent
conditions of growth and induction of bacterial cells tested to
avoid its precipitation, cell lysis was performed using sarkosyl.
This procedure allowed us to solubilize GST-fused S-GMD,
which could then be puri¢ed by GSH-Sepharose. However,
immediately after cleavage by Prescission protease, the result-
ing 38.7 kDa protein formed a precipitate and could not be
quantitatively recovered as soluble and functional protein
(Fig. 1A), although small amounts of S-GMD were observed
by Western blot experiments (Fig. 1B). Puri¢cation of
M-GMD, also performed using the sarkosyl method, allowed
us to recover a soluble and catalytically functional protein.
This suggests that precipitation of S-GMD is not due to
an e¡ect exerted by sarkosyl per se, but rather results from
an incorrect folding during protein production by bacterial
cells.
Fig. 1. (A) SDS-PAGE of the three recombinant forms of GMD, obtained after puri¢cation from bacterial lysates (Section 2.1). 5 Wg of L-
GMD and M-GMD was loaded. Conversely, after proteolytic cleavage, S-GMD immediately formed a precipitate and could not recover in sig-
ni¢cant amounts as soluble protein. The corresponding eluate from GSH-Sepharose, analyzed by Coomassie brilliant blue R-250 staining, gave
only one band of approximately 70 kDa. This might correspond to the E. coli chaperonine protein dnaK, a well known contaminant of re-
combinant proteins, which is involved in the degradation of abnormal proteins [22]. Prestained molecular markers (Sigma): 193 kDa, K-macro-
globulin; 112 kDa, L-galactosidase; 86 kDa, fructose 6-phosphate kinase; 70 kDa, pyruvate kinase; 57 kDa, fumarase; 39.5 kDa, lactate dehy-
drogenase; 36 kDa, triosephosphate isomerase. (B) Western blot analysis and amino acid sequence of the three forms of recombinant GMD.
Approximately 50 ng of proteins was loaded for L-GMD and C-GMD. For S-GMD, the eluate from GSH-Sepharose was directly loaded on
the gel. Samples were subjected to SDS-PAGE on a 12% acrylamide gel and to blotting on a nitrocellulose membrane. Detection was achieved
using a rabbit polyclonal anti-bacterial GMD antibody [14] and by the ECL method (Section 2.2). Prestained molecular markers (New England
Biolabs): 175 kDa, MBP-L-galactosidase; 83 kDa, MBP-paramyosin; 62 kDa, glutamate dehydrogenase; 47.5 kDa, aldolase; 32.5 kDa, triose-
phosphate isomerase.
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3.2. Subunit structure and content of apoenzyme-bound
NADP+
In order to investigate their subunit structure, both L-GMD
and M-GMD were subjected to size exclusion chromatogra-
phy and treatment with the chemical crosslinker BS3, followed
by Western blot analysis. Size exclusion analysis revealed that
M-GMD eluted as a single peak corresponding to a homodi-
meric form of approximately 80 kDa (not shown). In order to
con¢rm the oligomeric structure of M-GMD, we treated this
protein with increasing concentrations of BS3, either alone or
in the presence of an excess BSA, as a competitor to avoid
non-speci¢c intramolecular crosslinking (Fig. 2). Reaction of
M-GMD alone with BS3 reproducibly led to the appearance
of additional immunoreactive bands, with apparent Mr values
consistent mainly for dimers and for a small amount of tet-
ramers and to the concurrent decrease of the monomeric
form. In the presence of BSA, BS3 treatment generated a
similar pattern, but the extent of disappearance of the mono-
mer was considerably less pronounced and the band corre-
sponding to the dimeric form exhibited a slightly increased
mobility, which might be explained by assuming a lower ex-
tent of intramolecular crosslinking of M-GMD dimers by
BS3. Strictly comparable results from gel permeation and
BS3 crosslinking experiments were also obtained for the L-
GMD form (not shown).
Determination of GMD-bound coenzymes was performed
both on extensively dialyzed, native GMD forms and, follow-
ing their heat denaturation, on the corresponding superna-
tants (Table 1). No NAD could be detected in either con-
dition. Conversely, NADP was found to be present in
comparable amounts in the L-GMD and M-GMD forms.
While low contents of NADP, accounting for 0.14^0.2
mol/mol protein monomer, were detectable in the two native
GMD forms, higher dinucleotide levels were measured follow-
ing their heat denaturation (Table 1). These data indicate that
1 mol of NADP is tightly bound to either GMD homodi-
meric form, since it is dialysis-resistant, is not easily accessible
for the cycling reaction and can be released after denaturation
of the protein only.
3.3. Kinetic properties of L-GMD and M-GMD
The kinetic properties of L-GMD and M-GMD are re-
ported in Table 1. Both forms displayed comparable values
of Km and Vmax, which were consistent in several preparations
of the recombinant proteins and their activity was not a¡ected
by the addition of divalent cations (not shown). The Km ob-
tained for the recombinant proteins was comparable to that
previously determined in cell lysates [14] and also with GMD
puri¢ed from porcine thyroid [6]. No e¡ect whatsoever on the
enzymatic activity was observed upon addition of NAD or
NADP and of their reduced forms. GMD showed a pH
optimum around 7.5 and also exhibited maximal stability at
pH 7.5^8.0 (not shown). Both forms, L-GMD and M-GMD,
proved to be quite unstable, with a 50% loss of activity in 24^
36 h at 4‡C, which could not be prevented by addition of
reducing agents. Similarly, a signi¢cant decrease of speci¢c
activity was observed upon freezing, even in the presence of
cryoprotective agents such as glycerol.
Table 2 reports the potency of various inhibitors of GMD
activity. GDP-L-fucose, and in particular the L-anomer, was
the most active inhibitor, in agreement with the previously
reported data [13,17], while the other guanine derivatives
were much less e¡ective. Interestingly, no e¡ect was observed
with free L-fucose or its phosphorylated form, thus indicating
that the presence of the guanylic moiety is essential for rec-
ognition by the enzyme. No signi¢cant di¡erences were ob-
served between L-GMD and M-GMD as far as the inhibiting
e¡ects are concerned. Double-reciprocal plot analysis of the
kinetic data indicated that GDP-L-fucose behaves as a classi-
cal non-competitive inhibitor, with a Ki of 11.25 þ 1.7 WM,
while a competitive type of inhibition was observed for
GDP and GDP-D-glucose (not shown).
3.4. Cell distribution of L-GMD and M-GMD
Fig. 3 shows the results of Western blot experiments per-
formed on lysates from several human cell lines. In all sam-
ples, an immunoreactive band was observed with an apparent
Mr of 40 kDa, corresponding to the expected mass for M-
GMD, which seems therefore to be the predominant form of
the native enzyme. Additional distinct immunoreactive bands
were present. In particular, a second band band showing an
electrophoretic mobility comparable to standard L-GMD was
observed in the MCF-7 cell line, suggesting that also the form
Fig. 2. Western blot analysis of M-GMD after treatment with two
di¡erent concentrations of BS3, either in the presence or absence of
BSA. 50 ng of protein was loaded in each lane and subjected to
SDS-PAGE on a 12% acrylamide gel. Detection was achieved using
an anti-GMD antibody by the ECL method (Section 2.2). Markers
were from New England Biolabs (see Fig. 1B).
Table 1
NADP content and kinetic properties of L-GMD and M-GMD
NADP a (mol/mol of protein) Km (WM) Vmax (Wmol/h/mg) Kcat (s31) Kcat/Km (M31 s31)
Native Denatured
L-GMD 0.20 þ 0.07 0.56 þ 0.05 3.64 þ 1.2 37.9 þ 2.6
0.8 2.2U105
M-GMD 0.14 þ 0.05 0.47 þ 0.14 3.50 þ 0.7 40.0 þ 6.5
aNADP was determined on both native and heat-denatured GMDs and after heat denaturation by an enzymatic cycling assay, after extensive
dialysis of the puri¢ed recombinant proteins. Data are expressed as mol of dinucleotide per mol of monomeric protein.
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starting in correspondence of the ¢rst methionine is possibly
produced in these cells. Other bands showing a faster electro-
phoretic mobility, in particular one of approximately 35 kDa,
were also observed (mostly in HepG2 cells), which could not
be related to the previously proposed [15], shortest 38.7 kDa
form of GMD. Since precautions were taken to prevent arti-
factual proteolysis during cell lysis (Section 2.4), these forms
may represent ‘in vivo’ occurring proteolytic products, whose
role is presently unknown.
4. Discussion
GMD is a key enzyme in the ‘de novo’ biosynthesis of
GDP-L-fucose and, accordingly, also plays a fundamental
role in the control of the production of fucosylated oligosac-
charides. Puri¢cation of this enzyme from mammalian sour-
ces, in particular from human tissues, proved to be di⁄cult
because of its intrinsic instability (Tonetti, M., unpublished
results) and this prevented a detailed study of its enzymatic
and structural properties. The recent cloning of the cDNA for
human GMD has enabled us to produce the recombinant
protein [13,14]. However, three di¡erent protein species could
be expected from the proposed cDNA sequences and it was
completely unknown which form is really expressed in human
cells or whether a tissue or cell speci¢city is present.
Analysis of the sequence £anking the two possible initiating
AUG codons did not indicate the presence of an ideal Kozak
consensus sequence for either L-GMD and M-GMD, but a
suboptimal context for translational initiation is present in
both forms (including a purine in position 33 and a G in
position +4) [23]. Western blot analyses on human cell lysates
indicated that M-GMD represents the predominant form of
the enzyme, while a band corresponding to the L-GMD form
was found in signi¢cant amounts in only one of the cell lines
tested (MCF-7, see Fig. 3). Analysis of the structural and
kinetic properties of the two puri¢ed enzyme forms showed
an identical behavior for L-GMD and M-GMD, but it is not
yet clear whether the two forms display identical or di¡erent
properties also in the intracellular environment, where post-
translational control mechanisms could be involved.
The third form which has been proposed [15] and which
displays a 5P-untranslated region completely di¡erent from
the previously proposed sequence [13], corresponding to S-
GMD, lacks part of the N-terminal region compared to L-
GMD and M-GMD. This domain is extremely well-con-
served, not only among the GMDs from di¡erent organisms,
but also in most enzymes involved in the metabolism of nu-
cleoside diphosphate sugars [24], and it is essential for the
binding of the dinucleotide cofactor [25,26]. Therefore, its
absence and the consequent failure to bind NADP possibly
playing a structural role may prevent a correct folding of the
nascent S-GMD form and thus explain its lack of expression
both as a soluble and functional recombinant protein in E.
coli and also as S-GMD in any of the cell lines that we have
analyzed in this study.
Both M-GMD and L-GMD are homodimers, while bacte-
rial GMD [17] and the enzyme puri¢ed from porcine thyroid
[6] proved to be homohexamers, and each dimer binds one
molecule of NADP tightly. The presence of bound cofactor
playing a key role in catalysis was also suggested by the fact
that supplementation with NAD(P) had no e¡ect on the
enzymatic activity. This ¢nding is consistent with that de-
scribed by Broschat et al. [6] on puri¢ed porcine GMD. It
is, however, in contrast with what has previously been re-
ported for recombinant human GMD expressed in E. coli,
having N-terminal histidine-containing leader sequences,
which required the addition of exogenous NADP and also
of NADPH for activity [13]. The reason for this di¡erence is
not yet understood, but it is possible that the N-terminal tag,
which was not removed in the earlier study, might interfere
with the tight binding of NADP. A defective binding of the
dinucleotide to this recombinant protein is also strongly sug-
gested by the signi¢cant di¡erences observed in its kinetic
properties, with a 20-fold higher Km and a lower speci¢c ac-
tivity [13] compared to our data.
GDP-L-L-fucose is a strong feedback negative modulator of
GMD acting as a non-competitive inhibitor, while the other
nucleotides exhibit a competitive behavior. A non-competitive
mechanism of inhibition by GDP-L-fucose, together with the
low Ki value, suggests that this nucleotide sugar may represent
one of the most important mechanisms involved in the ‘in
vivo’ control of the GDP-L-fucose biosynthetic pathway.
The lack of any signi¢cant inhibitory e¡ect exerted by free
L-fucose and L-fucose-1-P indicates that the guanine moiety
is essential for the binding of the inhibitor. This ¢nding seems
to be relevant in the perspective to develop molecules able to
modulate activity of the GDP-L-fucose biosynthetic pathway
for therapeutic applications. In fact, molecules able to inter-
fere with the production of fucosylated glycoconjugates could
be useful as anti-in£ammatory or anti-allograft rejection
Table 2
E¡ects of inhibitors on M-GMD enzymatic activity
IC50 (mM)
GDP-L-L-fucose 0.024 þ 0.003
GDP-K-L-fucose 0.100 þ 0.017
GDP-D-glucose 0.530 þ 0.060
GDP 0.640 þ 0.100
GMP 0.700 þ 0.080
GTP 0.840 þ 0.170
L-Fucose s 2
L-Fucose-1-P s 2
ATP s 10
M-GMD activity was determined using 50 WM GDP-D-mannose in
the presence of di¡erent concentrations of inhibitors. Results are ex-
pressed as mean þ S.D. of the concentration required to give 50%
inhibition and were obtained from at least three independent experi-
ments. Closely comparable results were also obtained for L-GMD.
Fig. 3. Western blot analysis of human cell lines, performed using
an anti-bacterial GMD polyclonal antibody (Section 2.2). 50 ng of
standard GMD forms and 50 Wg of total cell proteins was loaded in
each lane. In order to minimize possible proteolytic degradation fol-
lowing cell lysis, cell cultures were directly lysed with boiling SDS-
PAGE loading bu¡er (Section 2.4). Lane 1: L-GMD, lane 2: M-
GMD, lane 3: S-GMD, lane 4: HepG2, lane 5: Hct-8, lane 6:
MCF-7, lane 7: Jurkat, lane 8: SKNSH. Markers were from New
England Biolabs (Fig. 1B). For explanations, see text.
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drugs, by preventing the selectin-mediated interaction between
leukocytes and endothelial cells which is preluded to extrava-
sation in tissues.
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